Drug Search Results
More Filters [+]

Sodium thiosulfate

Alternative Names: sodium thiosulfate, pedmark, nithiodote
Latest Update: 2024-06-28
Latest Update Note: Clinical Trial Update

Product Description

Sodium thiosulphate (STS), an antioxidant and calcium chelating agent, has been used for the treatment of calciphylaxis. However, its efficacy and safety have not been systematically analysed and evaluated. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28603903/)

Mechanisms of Action: Cyanide Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Belgium | Chile | China | Colombia | Dominican Republic | European Medicines Agency | France | Germany | Greece | Hong Kong | Iceland | India | Lithuania | Malaysia | New Zealand | Russia | Slovakia | Spain | Sweden | Taiwan | Thailand | United Kingdom | United States | Vietnam

Approved Indications: Oncology Solid Tumor Unspecified | Oncology Unspecified

Known Adverse Events: Hypernatremia | Hypokalemia

Company: American Regent
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodium thiosulfate

Countries in Clinic: Belgium, France, Germany, Netherlands, Spain, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Dermatitis, Allergic Contact|Dermatitis, Contact

Phase 2: Breast Cancer|Dermatomyositis|Head and Neck Cancer|Hypopharyngeal Cancer|Laryngeal Cancer|Mouth Cancer|Oropharyngeal Cancer|Papilloma|Scleroderma, General|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2023-507972-35-01

P3

Not yet recruiting

Dermatitis, Allergic Contact|Dermatitis, Contact

2026-01-01

NCI-2020-05752

P2

Completed

Hypopharyngeal Cancer|Mouth Cancer|Squamous Cell Carcinoma|Oropharyngeal Cancer|Papilloma|Head and Neck Cancer|Laryngeal Cancer

2023-05-31

BYON5667.002

P2

Completed

Breast Cancer

2023-04-19

57%

BYON5667.002

P2

Completed

Breast Cancer

2023-04-19

57%

ITS Pilot

P2

Active, not recruiting

Dermatomyositis|Scleroderma, General

2021-10-16

Recent News Events